High Throughput Screening of a GlaxoSmithKline Protein Kinase Inhibitor Set Identifies an Inhibitor of Human Cytomegalovirus Replication that Prevents CREB and Histone H3 Post-Translational Modification

Autor: Khan, AS, Murray, MJ, Ho, CMK, Zuercher, WJ, Reeves, MB, Strang, BL

To identify new compounds with anti-human cytomegalovirus (HCMV) activity and new anti-HCMV targets, we developed a high throughput strategy to screen a GlaxoSmithKline (GSK) Published Kinase Inhibitor Set (PKIS). This collection contains a range of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::e242e8e09b3ad1ad36b2f84a16b7f1f5
https://openaccess.sgul.ac.uk/id/eprint/108546/7/jgv.0.000713.pdf

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19.

Autor: Salguero FJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., White AD; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Slack GS; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Fotheringham SA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Bewley KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Gooch KE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Longet S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Humphries HE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Watson RJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Hunter L; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Ryan KA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Hall Y; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Sibley L; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Sarfas C; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Allen L; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Aram M; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Brunt E; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Brown P; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Buttigieg KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Cavell BE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Cobb R; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Coombes NS; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Darby A; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Daykin-Pont O; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Elmore MJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Garcia-Dorival I; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Gkolfinos K; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Godwin KJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Gouriet J; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Halkerston R; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Harris DJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Hender T; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Ho CMK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Kennard CL; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Knott D; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Leung S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Lucas V; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Mabbutt A; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Morrison AL; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Nelson C; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Ngabo D; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Paterson J; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Penn EJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Pullan S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Taylor I; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Tipton T; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Thomas S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Tree JA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Turner C; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Vamos E; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Wand N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Wiblin NR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Charlton S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Dong X; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Hallis B; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Pearson G; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Rayner EL; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Nicholson AG; Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK., Funnell SG; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Hiscox JA; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; Infectious Diseases Horizontal Technology Centre (ID HTC), A*STAR, Singapore, Singapore., Dennis MJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Gleeson FV; Department of Oncology, Oxford University, Oxford, UK., Sharpe S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK., Carroll MW; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, UK. miles.carroll@phe.gov.uk.; Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, Oxford University, Oxford, OX3 7BN, UK. miles.carroll@phe.gov.uk.

Publikováno v: Nature communications [Nat Commun] 2021 Feb 24; Vol. 12 (1), pp. 1260. Date of Electronic Publication: 2021 Feb 24.

Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Autor: Proud PC; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Tsitoura D; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia., Watson RJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Chua BY; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia., Aram MJ; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Bewley KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Cavell BE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Cobb R; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Dowall S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Fotheringham SA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Ho CMK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Lucas V; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Ngabo D; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Rayner E; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Ryan KA; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Slack GS; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Thomas S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Wand NI; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Yeates P; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG., Demaison C; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia., Zeng W; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia., Holmes I; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia., Jackson DC; Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia., Bartlett NW; Viral Immunology and Respiratory Disease group and Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia., Mercuri F; Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia. Electronic address: fm@enarespiratory.com., Carroll MW; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG; Nuffield Dept of Medicine, Oxford University, Oxford, UK. Electronic address: miles.carroll@phe.gov.uk.

Publikováno v: EBioMedicine [EBioMedicine] 2021 Jan; Vol. 63, pp. 103153. Date of Electronic Publication: 2020 Dec 03.

Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins.

Autor: Beelontally R; Institute of Infection & Immunity, St George's, University of London, London, UK., Wilkie GS; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Lau B; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Goodmaker CJ; Institute of Infection & Immunity, St George's, University of London, London, UK., Ho CMK; Institute of Infection & Immunity, St George's, University of London, London, UK., Swanson CM; Department of Infectious Diseases, King's College London, London, UK., Deng X; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang J; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Gray NS; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Davison AJ; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK., Strang BL; Institute of Infection & Immunity, St George's, University of London, London, UK; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: bstrang@sgul.ac.uk.

Publikováno v: Antiviral research [Antiviral Res] 2017 Feb; Vol. 138, pp. 61-67. Date of Electronic Publication: 2016 Dec 09.